Christopher Hardy was arrested during a traffic stop while carrying over 1,000 small blue fentanyl pills marked 'M30.' He pleaded guilty to conspiracy to distribute fentanyl and heroin under federal drug trafficking statutes. Hardy had acquired the pills from suppliers in Minnesota and was transporting them to North Dakota for distribution through a network of sub-dealers.
At sentencing, the district court applied a guidelines enhancement under U.S.S.G. ยง 2D1.1(b)(13)(A), which increases penalties when defendants knowingly misrepresent or market fentanyl as another substance. This enhancement raised Hardy's offense level from 23 to 27, resulting in a sentencing range of 100-125 months instead of a lower range. The court ultimately sentenced Hardy to 100 months in prison.
Hardy appealed the enhancement, arguing there was no evidence he had misrepresented the pills or marketed them as something other than fentanyl. He contended that blue 'M30' pills are synonymous with fentanyl in illegal drug markets, meaning buyers would know they were purchasing fentanyl rather than oxycodone.
The Eighth Circuit rejected Hardy's arguments, relying on its recent decision in United States v. Salinas involving similar facts. The court found that Hardy's placement of the deceptively marked pills into the drug market constituted 'marketing' under the guidelines enhancement, even without direct misrepresentation to individual buyers.
Crucially, Hardy had conceded in his sentencing memorandum that legitimate pharmaceuticals like oxycodone and clorazepate dipotassium frequently have blue coloration and 'M30' markings. He provided no evidence that fentanyl is legitimately sold in this form or that illegal drug purchasers exclusively associate such markings with fentanyl rather than prescription opioids.